11/21/2014, RB spin-out Indivior says addiction pipeline will deliver

http://www.pharmaphorum.com/news/rb-spin-out-indivior-says-addiction-pipeline-will-deliver

“At the moment, patients have to decide every day whether to stay in treatment – that’s 365 dosing decisions every year – and we can reduce that down to 12.” The product is injected subcutaneously and forms a gel pellet that breaks down slowly over the course of a month…

A similar philosophy underpins Indivior’s new buprenorphine product based on a prodrug – called buprenorphine hemiadipate – which means it can be formulated into a swallowable rather than a sublingual tablet…

While these are all important new products from a clinical perspective, the biggest commercial opportunity will probably come from Indivior’s alcohol dependence treatment arbaclofen placarbil…

Thaxter also said that, as an independent company, Indivior will be actively looking for opportunities to expand its pipeline in the addiction arena with technologies applicable to alcohol, cocaine, methamphetamine and cannabis dependence, among others…

http://www.fiercepharma.com/story/sales-slump-reckitt-pharma-spinoff-indivior-its-first-ever-earnings-release/2015-02-11

2/11/2015, Sales slump for Reckitt pharma spinoff Indivior in its first-ever earnings release

https://clinicaltrials.gov/ct2/show/NCT01848054

5/2/2013, Study to Assess OX219 (Buprenorphine/Naloxone) for the Induction of Treatment of Opioid Dependence

OX219 (Buprenorphine/Naloxone) [Zubsolv®]

Principal Investigator: Lynn Webster Life Tree Pain Clinic, 3838 S 700 E Suite 200, Salt Lake City, UT 84106

Sponsor:  Orexo AB

No Study Results Posted on ClinicalTrials.gov for this Study

Study Completion Date: January 2014

http://www.purduepharma.com/news-media/2010/07/purdue-pharma-l-p-receives-fda-approval-for-butrans-buprenorphine-transdermal-system-ciii/

7/1/2010, Purdue Pharma L.P. Receives FDA Approval for Butrans™ (buprenorphine) Transdermal System CIII

“Healthcare professionals now have an important new option for appropriate adult patients suffering from moderate to severe chronic pain when an opioid may be needed to manage their pain,” said Lynn R. Webster, MD, FACPM, FASAM, Medical Director of the Lifetree Clinical Research and Pain Clinic in Salt Lake City, Utah…

http://www.bizjournals.com/prnewswire/press_releases/2011/03/25/NY71789

SAN CARLOS, Calif., March 25, 2011 /PRNewswire/ — PharmacoFore, Inc., a privately held biopharmaceutical company developing next-generation abuse-resistant prescription drugs, announced that Lynn R. Webster, M.D., FACPM, FASAM, Co-Founder and Medical Director of Lifetree Clinical Research, will introduce the Company’s novel technology during the 27th Annual American Academy of Pain Medicine (AAPM) Meeting.

Dr. Webster’s presentation, titled “New Opioid Formulations and Delivery Systems,” will feature PharmacoFore’s Bio-Activated Molecular Delivery™ (also referred to as Bio-MD™) and MPAR™ technologies…

http://bdsi.investorroom.com/2014-04-07-BioDelivery-Sciences-Announces-Four-BUNAVAIL-Abstracts-to-be-Presented-at-the-2014-American-Society-of-Addiction-Medicine-Annual-Conference

BUNAVAIL utilizes BDSI’s proprietary BioErodible MucoAdhesive (BEMA) technology to deliver buprenorphine for the maintenance treatment of opioid dependence, along with the opioid antagonist naloxone, which is intended to serve as an abuse deterrent…

Poster presentation by Lynn Webster, MD
Low-Dose Naloxone Provides an Abuse Deterrent Effect to Buprenorphine Doses

BEMA Buprenorphine is in Phase 3 clinical trials for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Pharmaceuticals. Clonidine Topical Gel for the treatment of painful diabetic neuropathy is currently in Phase 3 development…

http://www.drugandalcoholdependence.com/article/S0376-8716(14)01686-X/abstract

Abuse potential study of intravenous oxycodone hydrochloride alone or in combination with intravenous naltrexone in nondependent, recreational opioid users

ALO-02 is an opioid formulation intended to deter abuse; it comprises capsules filled with pellets of extended-release oxycodone hydrochloride surrounding sequestered naltrexone. The abuse potential (i.e., drug liking and high) of intravenous (IV) oxycodone combined with naltrexone, to simulate IV administration of crushed ALO-02 in solution, was compared with IV oxycodone alone and IV placebo in nondependent, recreational opioid users.

http://www.drugandalcoholdependence.com/article/S0376-8716(14)01706-2/abstract

Preliminary report of THC influence on subject ability to discriminate between active opioid and placebo in human abuse liability study

http://www.opioidrisk.com/node/884

ORT: Opioid Risk Tool

Reprinted With Permission from Lynn Webster, MD

Click to access presidents-message-2014-volume15-3.pdf

(2014) Pain and Suicide: The Other Side of the Opioid Story

Three days later I got a call from his daughter. Jack had died from a self-inflicted gunshot wound. He left a note saying he couldn’t live with the pain anymore…

One thought on “11/21/2014, RB spin-out Indivior says addiction pipeline will deliver

If you don't comment, I'll just assume you agree with me

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s